Cantor Fitzgerald maintains $118 target on Ultragenyx stock
Cantor Fitzgerald reaffirmed its Overweight rating and $118.00 price target for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company specializing in rare diseases. Currently ...
Seeking Alpha2d
‘We think the Mag7 are vulnerable’ - Cantor Fitzgerald
Cantor Fitzgerald came out and expressed concerns around the Magnificent Seven group, saying the stocks are “vulnerable,” suggesting that there could be a shift in fund flows towards different ...
CVS Health upgraded at Cantor Fitzgerald after Q4 beat
CVS Health (CVS) stock was upgraded by Cantor Fitzgerald to Overweight after the company posted strong Q4 results earlier in ...
Cantor Fitzgerald Holds Tether Convertible Bond, Howard Lutnick Says
Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...
US Senate panel advances Cantor Fitzgerald's Lutnick for Commerce Department chief
A U.S. Senate committee voted on Wednesday to advance President Donald Trump's nominee Howard Lutnick, billionaire chairman ...
Cantor Fitzgerald begins coverage of five in ‘GovTech’ with three buys
As previously reported last night, Cantor Fitzgerald initiated coverage of five Government Technology & Space, or “GovTech,” stocks, ...
Business Insider15d
Lam upgraded to Overweight at Cantor Fitzgerald, says ‘too good to wait’
Cantor Fitzgerald upgraded Lam Research (LRCX) to Overweight from Neutral with a price target of $100, up from $95. The firm had suggested under $70 as “close your eyes” level for Lam over the ...